

## Acquisition Brief — neuromax.ai



**Domain name / Asset offered:** neuromax.ai (*single asset; no other extensions included*)

**Purpose:** acquisition of a strategic banner to run a **Neuro/AI excellence program** (R&D, data, safety/ethics, clinical/industry partnerships).

### Contacts

Email • contact@neuromax.ai

Website • <https://www.neuromax.ai>

LinkedIn • <https://www.linkedin.com/company/neuromaxai>

---

### This document — who it's for, why

Decision-grade brief for **CEO / COO / CFO / CTO / Regulatory & Compliance** (digital health, medtech/BCI, neuro-AI, pharma, devices, deeptech).

Thesis: **owning the category language** creates operational and reputational edge.

**NEUROMAX.AI** is a neutral, memorable banner to align **R&D, Data, Clinical, Quality/Regulatory, Security & Ethics**.

---

### 1) One-page decision

**What it is.** A **strategic asset** (.ai) to **structure & signal** a Neuro/AI program: public portal, references, resources, ecosystem voice.

**What it changes.** A **single entry point** → clear governance, stronger partner/talent pull, shorter evaluation cycles, improved **time-to-trust**.

**What you can deploy today.**

- **“Neuro/AI — Readiness & Rollout”.** Use-case roadmap, data governance (privacy & security), ethics framework.
- **Resource center.** Good-practice guides (neuro-data, evaluation/robustness, safe-use), documentation templates.

- **Ecosystem voice.** Use cases (BCI, rehab, imaging, triage), sector milestone calendar, neutral partner briefs.

**Why it's defensible.** Exact term + .ai with C-suite readability; **semantic lock** as the ecosystem adopts your wording.

---

## 2) Context & milestones

2025–2030: acceleration of **Neuro/AI programs** (sensors, BCI, imaging, digital biomarkers), rising expectations on **data & safety**, and **governance/evaluation** (quality, risk management, traceability).

**Implication.** Immediate need for a neutral banner to orchestrate **R&D, data, safety/ethics, partnerships** and communication.

---

## 3) Three concrete deployments (orders of magnitude)

**A. Health/tech enterprise (group program).** Neuro/AI governance, portfolio selection, evaluation & risk framework. Impact: **–6 to –10% project time; €0.8–2.0M coordination/communication savings over 12–18 months.**

**B. Scale-up / Medtech / BCI vendor.** Instant credibility (public reference), shorter cycles, **+€1–3M pipeline** (by ACV/segment).

**C. Alliance / Institution (neutral hub).** Shared references, data & metric standards, **network effects.**

---

## 4) Strategic edge of the pack

Authority through **Neuro/AI language**. C-level clarity. **Defensive** (exact-match .ai, readable, memorable). **Re-use** of content, kits and relationships on a single surface (talent, partners, investors).

---

## 5) Market size & pressure

Strong investment momentum in **neurotechnology & digital health** (R&D, data, safety, evaluations). Buyers need a **narrative standard** and a **visible hub**; **NEUROMAX.AI** provides both.

---

## 6) CFO anchors (obligatory)

**6.1 Alternative cost — awareness & adoption.** Without an exact-match: 6–12-month

campaign, internal brand architecture, change management. **Order: €0.4–1.5M / 12–18 months.**

**6.2 Cost of delay.** Slip one budgeting cycle = rework, delayed partnerships, unselected dossiers. **Order: €0.8–2.0M / 12–18 months** (mid/large).

**6.3 Reusable synergies.** Under a **single banner**, each euro (content, kits, connectors, relationships) is **re-used** → shorter time-to-trust, faster cycles, lower unit costs.

---

## 7) Investment logic (no public pricing)

SEO & memorability (exact term). **Strategic premium** (language control + 2025–2028 window). **Budget lens:** instead of spreading **€0.4–1.5M** across campaigns/change, a **single asset** accelerates partner adoption and reduces trust-acquisition cost.

---

## 8) Related assets / bundle option (≤2)

- **neuralaccess.ai** — identity/access/consent (IAM/CIAM) to secure access to neuro-data. (*add-on, not included*)
- **bciaccess.com** — BCI access/consent protocols (interoperability & governance). (*add-on, not included*)  
(*No other names cited. No claims beyond scope.*)

## 9) Clean acquisition process (Legal/Finance)

**Scope of sale: neuromax.ai only.**

Escrowed transaction, fast technical transfer, invoice. Options: **cash / staggered 40-30-30 / bundle**. NDA and asset audit available.

**Legal notice:** descriptive name, **no affiliation; no medical claims.**

---

## 10) Contacts

Email • contact@neuromax.ai

Website • <https://www.neuromax.ai>

LinkedIn • <https://www.linkedin.com/company/neuromaxai>